Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients with Myelodysplastic Syndromes/Neoplasms (MDS): An Analysis from the International Consortium for MDS (icMDS) Validate DatabaseBenjamin Rolles, Valeria Santini, Jan Philipp Bewersdorf et al.|Blood|2024Cited by 5
Clinical Implications of <i>TP53</i> Mutations/Allelic State in Patients (Pts) with Myelodysplastic Syndromes/Neoplasms (MDS) Treated with Hypomethylating Agents (HMA)- a Multicenter, Retrospective Analysis from the Validate DatabaseTariq Kewan, Amer M. Zeidan, Jan Philipp Bewersdorf et al.|Blood|2023Cited by 1
Validation of the Composite Complete Response (cCR) Definitions in the International Working Group (IWG) 2023 Criteria in Patients (Pts) with Higher-Risk Myelodysplastic Syndromes/Neoplasms (HR-MDS) Treated with Hypomethylating Agents (HMA) - a Large, Multicenter, Retrospective Analysis from the Validate DatabaseJan Philipp Bewersdorf, Amer M. Zeidan, Tariq Kewan et al.|Blood|2023Cited by 1
Validation of the Molecular International Prognostic Scoring System (IPSS-M) in Patients (Pts) with Myelodysplastic Syndromes/Neoplasms (MDS) Who Underwent Allogenic Stem Cell Transplantation (HSCT)Tariq Kewan, Amer M. Zeidan, Jan Philipp Bewersdorf et al.|Blood|2023Cited by 1
Evaluation of the Molecular International Prognostic Scoring System (IPSS-M) in Patients (Pts) with Myelodysplastic Syndromes/Neoplasms (MDS) with Missing Molecular DataTariq Kewan, Amer M. Zeidan, Jan Philipp Bewersdorf et al.|Blood|2023Cited by 1